HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $39 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $39 price target.
Stocks · News reference
Nuvectis Pharma's NXP200 BRAF Inhibitor Receives China's Breakthrough Therapy Designation
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Cal-Maine Foods Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Analysts downgraded UiPath, Cal-Maine with several price-target cuts.
This Toast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday
Wall Street analysts changed outlook on top companies. Check out complete rating changes, including upgrades/downgrades, on our page.